Who Paid My Doc
Mohamed Akl
Urogynecology and Reconstructive Pelvic Surgery Mesa, AZ Medical Doctor
NPI 1154388171 CMS profile 142698
6632 E. Baseline Road, Suite 101, Mesa, AZ 85206
General payments
$6,234
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Mohamed Akl of Mesa, AZ is reported in the CMS Open Payments database as having received $6,234 across 38 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 48th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $48 | 2 | |
| 2023 | General | $123 | 5 | |
| 2022 | General | $92 | 5 | |
| 2021 | General | $131 | 4 | |
| 2020 | General | $5,136 | 14 | |
| 2019 | General | $705 | 8 |
Beside peers
- Mohamed Akl
- Urogynecology and Reconstructive Pelvic Surgery median
- Middle half of Urogynecology and Reconstructive Pelvic Surgery
- National median
In program year 2025, general payments to Mohamed Akl were reported at $48. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.
Show as a table
| Year | Mohamed Akl | Urogynecology and Reconstructive Pelvic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $705 | $799 | $319–$2,013 | $163 |
| 2020 | $5,136 | $384 | $158–$1,360 | $114 |
| 2021 | $131 | $641 | $247–$2,515 | $132 |
| 2022 | $92 | $843 | $347–$2,794 | $149 |
| 2023 | $123 | $819 | $308–$2,302 | $160 |
| 2024 | $0 | $882 | $306–$2,459 | $164 |
| 2025 | $48 | $779 | $301–$2,705 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 35 drugsPart D claims
2,751
Drug cost
$272,008
Branded share of claims
41.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 170 | $121,581 | |
| Gemtesa Vibegron | Brand | 94 | $64,496 | |
| Solifenacin Succinate | Generic | 369 | $17,556 | |
| Elmiron Pentosan Polysulfate Sodium | Brand | 18 | $12,405 | |
| Linzess Linaclotide | Brand | 21 | $11,423 | |
| Estradiol | Generic | 141 | $8,801 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 212 | $5,352 | |
| Cephalexin | Generic | 185 | $3,817 | |
| Heparin Sodium Heparin Sodium,porcine | Brand | 37 | $3,389 | |
| Methenamine Hippurate | Generic | 42 | $2,997 |
The 10 drugs with the highest cost, of 35 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 51 billing codesPaid by Medicare
$160,195
Medicare patients
425
Services billed
1,377
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 67% | |
| Arthritis | 59% | |
| Depression | 28% | |
| Osteoporosis | 27% | |
| Ischemic heart disease | 24% | |
| Chronic kidney disease | 24% | |
| Diabetes | 23% | |
| COPD | 14% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, garamycin, gentamicin, up to 80 mg J1580 | Office | 13 | 42 | $83 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 14 | 44 | $16 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
38 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urogynecology and Reconstructive Pelvic Surgery in Arizona
Related records
Urogynecology and Reconstructive Pelvic Surgery in Arizona
Practitioners in the same specialty and state, ranked by reported value.
All Urogynecology and Reconstructive Pelvic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Arizona
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.